Amgen announced that it will offer discounted, direct-to-consumer sales of Repatha, an injectable drug used to treat high cholesterol, through a new consumer portal.
In an Oct. 6 statement, the company said the move was “in support of the Trump Administration’s efforts to lower drug prices for Americans.”
The Thousand Oaks, California-based company joins Pfizer, which announced on Sept. 30 that Medicaid programs will have access to “most favored nation” pricing of its products, referring to President Donald Trump’s initiative to offer U.S. patients the lowest prices found in developed countries.
Amgen will offer Repatha directly to consumers through AmgenNow, a web-based platform it is developing. U.S. patients will be able to buy the medication for a monthly price of $239, about 60 percent below the current list price. …